tirzepatide mcas A newly published case series reports that GLP-1 receptor agonists (like semaglutide and tirzepatide) may significantly improve symptoms in patients with mast cell activation syndrome (MCAS), even in those without diabetes or Mast Cell Activation Syndrome (MCAS)

Jeppesen et al

Safety & Candidacy Ipamorelins selectivity distinguishes it from earlier growth hormone secretagogues, offering targeted GH support with minimal off-target effects and an excellent safety profile

Mientras que la semaglutida acta sobre un solo receptor (el del pptido-1 similar al glucagn, o GLP-1) y la tirzepatida sobre dos (los receptores del GLP-1 y del polipptido inhibidor gstrico, o GIP), la retatrutida recibi el apodo de "Triple G" por su capacidad para actuar sobre tres receptores hormonales (los del GLP-1, el GIP y el receptor del glucagn, o GCG)

Kurzbach et al., 2015

"Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers"

DJB was supported by fellowship (SFRH/BD/64939/2009) from FCT, Portugal